Clearmind Medicine (XCNQ:CMND) ROCE % : -190.96% (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Clearmind Medicine's annualized ROCE % for the quarter that ended in Jan. 2024 was -190.96%.

Clearmind Medicine ROCE % Historical Data

The historical data trend for Clearmind Medicine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine ROCE % Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

ROCE %

Get a 7-Day Free Trial

-57.45

-130.37

-101.69

-339.38

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-486.65	-154.59	-143.73	-316.37	-190.96

Clearmind Medicine ROCE % Calculation

Clearmind Medicine's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	-6.25	/	( ( (0.831 - 1.944)	+	(5.903 - 4.928) )	/ 2 )
	=	-6.25	/	( (-1.113	+	0.975)	/ 2 )
	=	-6.25	/	-0.069
	=	9,057.97 %

Clearmind Medicine's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-7.432	/	( ( (5.903 - 4.928)	+	(13.555 - 6.746) )	/ 2 )
	=	-7.432	/	( ( 0.975	+	6.809 )	/ 2 )
	=	-7.432	/	3.892
	=	-190.96 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Clearmind Medicine (XCNQ:CMND) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Clearmind Medicine ROCE % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (XCNQ:CMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CMND:USA CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.